Navigation Links
Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets
Date:1/4/2011

NEW YORK, Jan. 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Emerging Opportunities in Biosimilar and Biobetter Drugs Markets

http://www.reportlinker.com/p0357279/Emerging-Opportunities-in-Biosimilar-and-Biobetter-Drugs-Markets.html

Executive SummaryThe biosimilar and biobetter drugs market has started to position itself in a grand manner following a series of changes in regulatory framework in many countries. The biosimilar market segment represents a host of opportunities to the generics manufacturers to enter in a market, which is largely driven by commands premium prices and unmet needs. Backed by this feature, the market is continuing to outperform the global pharmaceutical market. "Emerging Opportunities in Biosimilar and Biobetter Drugs Markets" provides a detailed overview and a succinct, but deep-dive analysis on the biosimilar and biobetter drugs segments. The report discusses various exclusive features of biobetter drugs and studies their importance in meeting the future demand. It also highlights various emerging trends in the market and relates these with the future market growth.

The key objective of this report is to identify and probe into the emerging opportunities in the biobetter and biosimilar drugs market. It also tries to estimate the opportunities in various biological drugs segments including monoclonal antibodies, Erythropoietin and insulin, thus giving a complete idea about the market dynamics to the target audience of this report.

The report Emerging Opportunities in Biosimilar and Biobetter Drugs Markets also includes information on the key players in the industry and their product portfolio. This will enable the target audience of this report in understanding the contemporary industry scenario. Besides, the report gives complete information on various products whose patents are on the verge of expiration and thus, it is offering huge opportunities for generics manufacturers. Some of the key findings of report are given below:

  • The clause of "12 Year Exclusivity" for biologics in the US healthcare reform bill is going to have a long term impact on the growth of biosimilar drugs market
  • The increasing application of monoclonal antibodies in the cancer treatment is going to boost the demand of biosimilar and biobetter drugs in this market segment

  • Delivery TimeThree Business days

    To order this report:: Emerging Opportunities in Biosimilar and Biobetter Drugs Markets

    More  Market Research Report

    Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
    '/>"/>

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
    2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
    3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
    4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
    5. Reportlinker Adds Nanomedicine Report
    6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
    7. Reportlinker Adds Nanoporous Materials Report
    8. Reportlinker Adds Membrane Bioreactors Report
    9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
    10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
    11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2017)... , ... March 27, 2017 , ... ... accelerating the fight against cancer, autoimmune disease and more through a single-cell precision ... metabolomics and proteomics analysis platform developed in the laboratory of Dr. James ...
    (Date:3/27/2017)... Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today announced positive results of ... in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a new small molecule drug ... National Institutes of Health. Continue Reading ... ... ...
    (Date:3/27/2017)... The new research portal will give ... reports on Valero Energy , offering extensive market research ... ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) The latest trend gaining ... Ethanol today, even though touted as a green alternative to ...
    (Date:3/27/2017)... -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, ... Welch , will be presenting at this year,s MicroCap ... at the Essex House in New York ... Mark Erlander , Ph.D., will also be available ... The presentation will be webcast live at http://wsw.com/webcast/microcapconf3/trov ...
    Breaking Biology Technology:
    (Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
    (Date:3/13/2017)... March 13, 2017 Future of security: Biometric Face Matching ... ... DERMALOGs Face Matching enables to match face pictures against each ... to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching on ...
    (Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
    Breaking Biology News(10 mins):